Search results for "antibodies"
Article
Register to the Chromatography + Filtration Virtual Summit 2024
Agenda
Day 1:
- Chromatography for antibodies and antibody variants
Day 2:
- Chromatography for recombinant proteins
- Filtration for antibodies and other recombinant proteins
Da…
Article
Reimagining Affordable Biosimilars
For example, the glycosylation profile of antibodies made by a single Chinese hamster ovary (CHO) cell line will have several dozen forms of glycan-patterns. Each glycosylated variant of the antibody …
Article
Modeling the Degradation of mAb Therapeutics
This is particularly true for monoclonal antibodies (mAbs), which account for most commercial biopharmaceuticals today. Both physical effects such as aggregation and chemical modifications (e.g., frag…
Article
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic Drugs
For example, the time needed to achieve enzymatic deglycosylation of monoclonal antibodies has been reduced by nearly two orders of magnitude. Certain products (e.g., Rapid PNGase F, New England Biola…
Article
The Challenge of Disruptive Technologies in Bioprocessing
“The use of mAbs for Alzheimer’s disease (Biogen), influenza (VIR), or as neutralizing antibodies for HIV (JustBio) are examples where such demand could come up,” Jagschies says.
Other drivers …
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
This week Process Development Forum talks about Protein A with Jonathan Royce, business leader for Cytiva chromatography resins.
mAb purification platforms are very well established, and …
Article
N-Glycan Analysis of Biotherapeutic Proteins
More than half of all biotherapeutics are glycosylated (2), including monoclonal antibodies (mAbs), Fc-fusion proteins, clotting factors, and cytokines such as erythropoietin. Of these, mAbs represent…
Article
Cost Considerations Drive Lean Technology in Biopharmaceutical Manufacturing
Monoclonal antibodies (mAbs) are the most common and most well-known class of biopharmaceuticals. As of February 2017, FDA lists 68 approved mAbs, and approvals have been increasing each year since th…
Article
Platform Approach Speeds Process Development
By Harald Bradl, Jan Bechmann, Benedikt Greulich, Markus Michael Mueller, Patrick Schulz, Thomas Wucherpfennig
Commercial production of complex biopharmaceuticals such as recombinant monoclonal an…
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
This early screening approach has identified cryptic aberrant splice sites in multiple therapeutic candidates including monoclonal antibodies, bispecific antibodies, and fusion proteins, therefore pre…